Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm phase 2 trial of (+)-α-dihydrotetrabenazine for tardive dyskinesia
2024-519105-35-00Phase 2Suspended
- Sponsor
- Adeptio Pharmaceuticals
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of (+)-α-dihydrotetrabenazine in tardive dyskinesia (TD), sponsored by Adeptio Pharmaceuticals. Primary endpoints: AIMS Dyskinesia Total Score at week 8 versus baseline, Exploratory central blinded AIMS video rating and 1 more. Started Aug 2023; status: suspended.
02
Drugs
(+)-α-dihydrotetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on 2024-519105-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519105-35-00.